Real-world Study on the Prevention of Neutropenia After Tumor Treatment With Mecapegfilgrastim Injection

Inclusion Criteria:

• 1. Patients with malignant tumors confirmed by histopathology or cytology; 2. Age ≥18 years old; 3. After referring to various guidelines, the researchers believedthat the subjects:

1. Patients who are currently receiving treatment regimens with high FN risk;

2. Patients who are currently receiving treatment regimens for moderate FN riskand meet any one of the factors that increase the risk coefficient;

3. FN or dose-limiting neutropenia events have occurred in previous treatmentcycles;

4. In addition to the above, the researchers believe that the medication regimenswill cause neutropenia and affect the normal treatment of the subjects; 4.Researchers believe that they can benefit; 5. Voluntarily participate in thisclinical trial and be able to sign the informed consent form in person.

Exclusion Criteria:

• 1. Those who are allergic to the test drug； 2. Those with mental or neurologicaldisorders who are unable to cooperate； 3. Pregnant or lactating female patients;Women of childbearing age who refuse to take contraceptive measures； 4. Those whowere considered unsuitable for inclusion by the researchers.